Literature DB >> 12786610

Review article: maintenance treatment of Crohn's disease.

L Biancone1, C Tosti, D Fina, M Fantini, F De Nigris, A Geremia, F Pallone.   

Abstract

The aetiology of Crohn's disease is unknown and therefore no curative treatments are available for the disease. The natural history of Crohn's disease is characterized by recurrent flare-ups of symptoms. Several drug treatments are effective in inducing clinical remission. However, no drug treatments are available in order to prevent clinical relapses, although several drug regimens may delay clinical flare-ups. Crohn's disease treatment for maintaining clinical remission needs to be tailored in relation to specific characteristics of each patient. The frequency of clinical relapse indeed shows marked variations in subgroups of patients, as the likelyhood of relapse is higher in patients in clinical remission for less than 6 months. Treatment strategies for maintaining remission may therefore differ among inactive patients. In chronically active, steroid-dependent or steroid-refractory Crohn's disease patients immunomodulatory drugs (azathioprine 2-2.5 mg/kg by mouth, 6-mercaptopurine 1-1.5 mg/kg by mouth, or methotrexate 15-25 mg/i.m./week) should be added to oral mesalazine (2.4 g/day), while in long-term inactive Crohn's disease patients mesalazine alone may be effective in delaying relapse. Recently, treatment with anti-tumour necrosis factor-alpha monoclonal antibodies (Infliximab or CDP571) has shown efficacy in delaying relapse in responsive patients. One other issue which needs to be considered before selecting drug treatments for maintaining remission in Crohn's disease, is that Crohn's disease activity is currently assessed on the basis of standard clinical scores which may not appropriately reflect the biological activity of the disease. Clinical remission as defined by standardized scores may include heterogeneous subgroups of patients showing different endoscopic and histological activity or persistence of activated immunocompetent cells within the gut. Several sub-clinical markers of relapse have indeed been reported in quiescent Crohn's disease, although their usefulness in clinical practice in currently uncertain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786610     DOI: 10.1046/j.1365-2036.17.s2.20.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Phenotype at diagnosis predicts recurrence rates in Crohn's disease.

Authors:  F L Wolters; M G Russel; J Sijbrandij; T Ambergen; S Odes; L Riis; E Langholz; P Politi; A Qasim; I Koutroubakis; E Tsianos; S Vermeire; J Freitas; G van Zeijl; O Hoie; T Bernklev; M Beltrami; D Rodriguez; R W Stockbrügger; B Moum
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

2.  Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease.

Authors:  Dario Sorrentino; Claudio Avellini; Carlo Alberto Beltrami; Enrico Pasqual; Ester Zearo
Journal:  Int J Colorectal Dis       Date:  2005-06-11       Impact factor: 2.571

Review 3.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

4.  Increased feelings with increased body signals.

Authors:  Eduardo P M Vianna; Joel Weinstock; David Elliott; Robert Summers; Daniel Tranel
Journal:  Soc Cogn Affect Neurosci       Date:  2006-06       Impact factor: 3.436

5.  Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.

Authors:  Jin Li; Cheng Chen; Xiao-Nian Cao; Gui-Hua Wang; Jun-Bo Hu; Jing Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-02-06

6.  A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.

Authors:  Gary R Lichtenstein; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Robert H Diamond; Marion Blank; Jennifer Montello; Linda Tang; Freddy Cornillie; Jean-Frédéric Colombel
Journal:  Am J Gastroenterol       Date:  2012-05-22       Impact factor: 10.864

7.  Enteral nutrition for maintenance of remission in Crohn's disease.

Authors:  Anthony K Akobeng; Dongni Zhang; Morris Gordon; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2018-08-11

8.  Uygur medicine Xipayi Kui Jie'an affects gene expression profiles in intestinal tissue lesions in a rat model of ulcerative colitis.

Authors:  Kurexi Yunusi; Jingping Zhang; Li Zhong; Gulinisha Mosha; Ajiguli Nuermaimaiti; Mairipaiti Abudula; Halmurat Upur
Journal:  BMC Complement Altern Med       Date:  2015-05-22       Impact factor: 3.659

9.  Effects of glucocorticoids combined with probiotics in treating Crohn's disease on inflammatory factors and intestinal microflora.

Authors:  Hui Su; Qian Kang; Haihong Wang; Hui Yin; Linghui Duan; Yuli Liu; Ruying Fan
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

10.  A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease.

Authors:  Audrey Bennett; Lauren Evers Carlini; Caroline Duley; Ailish Garrett; Kim Annis; Julianne Wagnon; Robin Dalal; Elizabeth Scoville; Dawn Beaulieu; David Schwartz; Sara Horst
Journal:  Crohns Colitis 360       Date:  2020-02-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.